logo
Home
Products
Mission
News
Reviews
Pharmaceutical oversight
Contacts
Gallery

Oncologic diseases

In the studies of Т.А. Ageeva et al. (2001) who used the scheme “cyclophosphane-vincristin-prednizolone” for therapy of transplanted lymphosarcoma, it has been registered that administration of Enterosgel to animals decreased an expression of damage of parenchymatosis liver cells and decreased concentration of «medium molecules» in blood serum to 433±0.043 rel.u. versus 0.704±0.037 rel.u. in control without alteration of chemotherapeutic results.

By the opinion of some researchers (О.P. Kaban et al., 1997, 2001; L.М. Gunina et al., 1997), Enterosgel is a useful mean for application in oncosurgery allowing, in particular, to decrease the number of postsurgical complications and relieve the course of postsurgical period in patients with mechanical jaundice, improve indexes of enteric microbiocenosis, decrease concentration of «medium molecules» and decrease intensity of local proteolysis.

By the data of these authors, Enterosgel use in patients undergoing intense courses of polychemotherapy, decreased intensity of nausea and vomiting, decreased the value of hematological indexes of intoxication, improved structural-functional state of erythrocyte membrane. The part of patients with expressed (< 2 ´ 109/l) leucopenia reduced at average from 33 to 18 %, whilst in patients undergoing chemotherapy due to tumors of digestive system, these differences were 21.2 % versus 54.6% in control. L.V. Guta (1997) consider administration of Enterosgel during polychemotherapy of ovarian cancer of  III – IV stages useful one, noting better tolerability of treatment and decrease of plasma concentration of «medium molecules» in these patients. M.I. Loseva et al. (1999) have used Enterosgel for therapy of patients with acute lymphoblastic and myeloid leucosis, and have registered along with a number of positive biochemical and clinical effects more rapid  remission of the patients.